

**Amendments to the Claims:**

1. (Currently Amended) A method for treating restenosis comprising an intravascular infusion or delivery by release from a surface of a stent of a combination of at least two agents, including an anti-proliferative agent for inhibiting smooth muscle cell growth comprising rapamycin or an analogue thereof and an anti-inflammatory agent for inhibiting smooth muscle growth, both said layers contained in therapeutic dosage amounts.

2. (Canceled)

3. (Previously Amended) The method of claim 1 wherein the anti-inflammatory agent comprises dexamethasone.

4. (Previously Amended) The method of claim 1 wherein the combination of at least two agents further includes a growth factor or cytokine signal transduction inhibitor.

5. (Previously Amended) The method of claim 4 wherein the cytokine signal transduction inhibitor comprises a ras inhibitor, R115777, and the anti-proliferative agent is taken from a group consisting of rapamycin, taxol, or vincristine.

6. (Previously Amended) The method of claim 1 wherein the combination of at least two agents further includes a tyrosine kinase inhibitor.

7. (Previously Amended) The method of claim 6 wherein the tyrosine kinase inhibitor comprises tyrphostin and the anti-proliferative agent is taken from a group consisting of rapamycin, taxol, vincristine.

8. (Previously Amended) The method of claim 1 wherein the combination of at least two agents further includes an inhibitor of extracellular matrix synthesis.

Serial No. 09/575,480  
CRD-850

9. (Previously Amended) The method of claim 8 wherein the inhibitor of extracellular matrix synthesis comprises halofuginone and the anti-proliferative agent is taken from a group consisting of rapamycin, taxol, or vincristine.

10. (Canceled)

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)